(Q34615157)

3 August 2017

title

Current therapy for autoimmune hepatitis (English)

1 reference

3 August 2017

Aldo J Montano Loza

1

1 reference

3 August 2017

Albert J Czaja

series ordinal

2

1 reference

3 August 2017

language of work or name

English

0 references

publication date

1 April 2007

1 reference

Nature Reviews Gastroenterology & Hepatology

3 August 2017

published in

1 reference

3 August 2017

volume

4

1 reference

3 August 2017

issue

4

1 reference

3 August 2017

page(s)

202-214

1 reference

Mycophenolate mofetil for the treatment of autoimmune hepatitis in patients refractory to standard therapy

3 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0768

Budesonide induces complete remission in autoimmune hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0768

Side effects of budesonide in liver cirrhosis due to chronic autoimmune hepatitis: influence of hepatic metabolism versus portosystemic shunts on a patient complicated with HCC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0768

Diagnosis and treatment of autoimmune hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0768

7 January 2021

Evolving new therapies of autoimmune hepatitis

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0768

7 January 2021

Treatment of autoimmune hepatitis

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0768

7 January 2021

Autoimmune hepatitis: effect of symptoms and cirrhosis on natural history and outcome.

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0768

7 January 2021

Meeting report: International Autoimmune Hepatitis Group

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0768

7 January 2021

Recurrent autoimmune hepatitis after orthotopic liver transplantation

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0768

7 January 2021

De-novo autoimmune hepatitis after liver transplantation

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0768

7 January 2021

Graft dysfunction mimicking autoimmune hepatitis following liver transplantation in adults.

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0768

7 January 2021

Prognosis of symptomatic versus asymptomatic autoimmune hepatitis: a study of 68 patients

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0768

7 January 2021

Duration of immunosuppressive therapy in autoimmune hepatitis

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0768

7 January 2021

Factors predicting relapse and poor outcome in type I autoimmune hepatitis: role of cirrhosis development, patterns of transaminases during remission and plasma cell activity in the liver biopsy

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0768

7 January 2021

Persistent normalization of serum alanine aminotransferase levels improves the prognosis of type 1 autoimmune hepatitis

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0768

7 January 2021

Persistent elevation of serum alanine aminotransferase levels leads to poor survival and hepatocellular carcinoma development in type 1 autoimmune hepatitis

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0768

7 January 2021

Prognosis of histological cirrhosis in type 1 autoimmune hepatitis.

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0768

7 January 2021

Type I autoimmune hepatitis: clinical course and outcome in an Italian multicentre study.

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0768

7 January 2021

Sustained remission after corticosteroid therapy for type 1 autoimmune hepatitis: a retrospective analysis

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0768

7 January 2021

Decreased fibrosis during corticosteroid therapy of autoimmune hepatitis

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0768

7 January 2021

Autoimmune hepatitis in African Americans: presenting features and response to therapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0768

7 January 2021

Efficacy of ursodeoxycholic acid in Japanese patients with type 1 autoimmune hepatitis

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0768

7 January 2021

Characteristics of autoimmune hepatitis in patients who are not of European Caucasoid ethnic origin

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0768

7 January 2021

Autoimmune hepatitis in childhood: a 20-year experience.

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0768

7 January 2021

Distinctive clinical phenotype and treatment outcome of type 1 autoimmune hepatitis in the elderly

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0768

7 January 2021

Autoimmune hepatitis in the elderly

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0768

7 January 2021

Diagnosis and treatment of autoimmune hepatitis at age 65 and older

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0768

7 January 2021

Clinical features of type 1 autoimmune hepatitis in elderly Italian patients

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0768

7 January 2021

Autoimmune hepatitis (AIH) in the elderly: a systematic retrospective analysis of a large group of consecutive patients with definite AIH followed at a tertiary referral centre

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0768

7 January 2021

Clinical characteristics of autoimmune hepatitis in older aged patients

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0768

7 January 2021

Genetic susceptibilities for immune expression and liver cell injury in autoimmune hepatitis

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0768

7 January 2021

Genetic bases of autoimmune hepatitis.

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0768

7 January 2021

Associations between alleles of the major histocompatibility complex and type 1 autoimmune hepatitis

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0768

7 January 2021

Cytokine polymorphisms associated with clinical features and treatment outcome in type 1 autoimmune hepatitis

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0768

7 January 2021

Cytotoxic T lymphocyte antigen-4 (CTLA-4) gene polymorphisms and susceptibility to type 1 autoimmune hepatitis

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0768

7 January 2021

Genetic association of vitamin D receptor polymorphisms with primary biliary cirrhosis and autoimmune hepatitis

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0768

7 January 2021

77 C/G mutation in the tyrosine phosphatase CD45 gene and autoimmune hepatitis: evidence for a genetic link

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0768

7 January 2021

Allelic basis for HLA-encoded susceptibility to type 1 autoimmune hepatitis

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0768

7 January 2021

Autoimmune hepatitis overlapping with primary sclerosing cholangitis in five cases

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0768

7 January 2021

Frequency and nature of the variant syndromes of autoimmune liver disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0768

7 January 2021

Treatment strategies in autoimmune hepatitis

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0768

7 January 2021

Thiopurine methyltransferase phenotype and genotype in relation to azathioprine therapy in autoimmune hepatitis

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0768

7 January 2021

Thiopurine methyltransferase deficiency and azathioprine intolerance in autoimmune hepatitis

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0768

7 January 2021

Utility of thiopurine methyltransferase genotyping and phenotyping, and measurement of azathioprine metabolites in the management of patients with autoimmune hepatitis

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0768

7 January 2021

Low-dose corticosteroid therapy after multiple relapses of severe HBsAg-negative chronic active hepatitis

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0768

7 January 2021

Azathioprine for long-term maintenance of remission in autoimmune hepatitis

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0768

7 January 2021

Long-term follow-up after liver transplantation for autoimmune hepatitis: evidence of recurrence of primary disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0768

7 January 2021

Allograft rejection after liver transplantation for autoimmune liver diseases

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0768

7 January 2021

Rapamycin successfully treats post-transplant autoimmune hepatitis

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0768

7 January 2021

Features reflective of early prognosis in corticosteroid-treated severe autoimmune chronic active hepatitis

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0768

7 January 2021

Early treatment response predicts the need for liver transplantation in autoimmune hepatitis

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0768

7 January 2021

Current and novel immunosuppressive therapy for autoimmune hepatitis

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0768

7 January 2021

Short-term cyclosporine induces a remission of autoimmune hepatitis in children.

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0768

7 January 2021

Cyclosporin A is a promising alternative to corticosteroids in autoimmune hepatitis

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0768

7 January 2021

Efficacy of tacrolimus in the treatment of steroid refractory autoimmune hepatitis

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0768

7 January 2021

Mycophenolate mofetil for maintenance of remission in autoimmune hepatitis in patients resistant to or intolerant of azathioprine.

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0768

7 January 2021

Transplant immunosuppressive agents in non-transplant chronic autoimmune hepatitis: the Canadian association for the study of liver (CASL) experience with mycophenolate mofetil and tacrolimus

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0768

7 January 2021

Empiric therapy of autoimmune hepatitis with mycophenolate mofetil: comparison with conventional treatment for refractory disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0768

7 January 2021

Oral budesonide for treatment of autoimmune chronic active hepatitis.

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0768

7 January 2021

Budesonide in previously untreated autoimmune hepatitis.

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0768

7 January 2021

Failure of budesonide in a pilot study of treatment-dependent autoimmune hepatitis

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0768

7 January 2021

The successful treatment of autoimmune hepatitis with 6-mercaptopurine after failure with azathioprine

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0768

7 January 2021

Promising treatment of autoimmune hepatitis with 6-thioguanine after adverse events on azathioprine

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0768

7 January 2021

On the limitation of 6-tioguaninenucleotide monitoring during tioguanine treatment

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0768

7 January 2021

Successful treatment of autoimmune hepatitis and idiopathic thrombocytopenic purpura with the monoclonal antibody, rituximab: case report and review of literature

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0768

7 January 2021

Autoimmune hepatitis associated with infliximab in a patient with psoriatic arthritis

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0768

7 January 2021

Synthetic peptides that inhibit binding of the collagen type II 261-273 epitope to rheumatoid arthritis-associated HLA-DR1 and -DR4 molecules and collagen-specific T-cell responses

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0768

7 January 2021

Transplantation of anergic histoincompatible bone marrow allografts

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0768

7 January 2021

Oral tolerance in the treatment of inflammatory autoimmune diseases

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0768

7 January 2021

Suppression of murine experimental autoimmune hepatitis by T-cell vaccination or immunosuppression

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0768

7 January 2021

How to modulate inflammatory cytokines in liver diseases

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0768

7 January 2021

A pilot study of the safety and tolerability of etanercept in patients with alcoholic hepatitis

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0768

7 January 2021

A double-blind randomized controlled trial of infliximab associated with prednisolone in acute alcoholic hepatitis

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0768

7 January 2021

Identifiers

DOI

10.1038/NCPGASTHEP0768

1 reference

3 August 2017

1 reference